TrialBMC cancer2016

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.

Eva Segelov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.